PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Jonathan S T Sham Selected Research
Carcinoma (Carcinomatosis)
07/2008
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.
10/2007
Stereotactic radiosurgery versus gold grain implantation in salvaging local failures of nasopharyngeal carcinoma.
11/2006
Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
09/2006
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
08/2006
Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: results of a prospective longitudinal study.
08/2006
Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials.
01/2006
Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma.
12/2005
Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy.
10/2005
Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.
10/2005
Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma.
07/2005
A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
02/2005
Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials.
01/2005
Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma.
10/2004
Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
10/2004
Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function.
07/2004
Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone.
07/2004
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
05/2004
Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.
02/2004
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
07/2003
EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
06/2003
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
10/2002
Significance of scheduling on the cytotoxicity of radiation and cisplatin combination treatment in nasopharyngeal carcinoma cells.
04/2002
Control of regional metastasis after induction chemotherapy and radiotherapy for nasopharyngeal carcinoma.
Articles by Research Topic
Disease
23
Carcinoma (Carcinomatosis)
07/2008 - 04/2002
3
Hepatocellular Carcinoma (Hepatoma)
07/2007 - 08/2002
3
Neoplasm Metastasis (Metastasis)
07/2007 - 04/2002
2
Nasopharyngeal Neoplasms (Cancer of the Nasopharynx)
04/2008 - 10/2005
2
Neoplasms (Cancer)
07/2007 - 11/2005
1
Xerostomia
11/2006
1
Glioblastoma (Glioblastoma Multiforme)
11/2005
1
Ovarian Neoplasms (Ovarian Cancer)
06/2004
1
Liver Neoplasms (Liver Cancer)
01/2004
Drug/Important Bio-Agent (IBA)
5
Cisplatin (Platino)
FDA Link
Generic
10/2005 - 10/2002
3
Epidermal Growth Factor Receptor (EGF Receptor)
IBA
01/2006 - 05/2004
2
capecitabine (Xeloda)
FDA Link
04/2008 - 06/2003
2
Fibroblast Growth Factor 3
IBA
07/2007 - 01/2006
2
DNA (Deoxyribonucleic Acid)
IBA
10/2004 - 07/2003
1
gefitinib (Iressa)
FDA Link
07/2008
1
Gold
IBA
10/2007
1
Carbon Monoxide
IBA
01/2006
1
gemcitabine
FDA Link
10/2005
1
docetaxel (Taxotere)
FDA Link
07/2005
1
Clusterin
IBA
01/2005
1
Hemoglobins (Hemoglobin)
IBA
07/2004
1
eIF-5A2
IBA
06/2004
1
Fluorouracil (Carac)
FDA Link
Generic
02/2004
1
Ifosfamide
FDA Link
Generic
02/2004
1
Leucovorin (Folinic Acid)
FDA Link
Generic
02/2004
1
Vimentin
IBA
01/2004
1
Interleukin-4 (Interleukin 4)
IBA
01/2004
1
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
01/2004
1
Platinum
IBA
06/2003
1
Hepatitis B Surface Antigens (HBsAg)
IBA
08/2002
Therapy/Procedure
9
Drug Therapy (Chemotherapy)
09/2006 - 04/2002
4
Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
11/2006 - 10/2004
2
Adjuvant Chemotherapy
07/2004 - 02/2004